GATC Biotech AG, a German DNA sequencing service provider, said it has signed a collaboration agreement with three partners to develop a DNA microarray-based diagnostic test able to detect both bacterial and fungal sepsis-triggering pathogens
The chairman of Allergy Therapeutics Plc said he expects the FDA hold on its clinical trials of Pollinex Quattro to be lifted in due course.
Omega Pharma NV is spinning out its professional health division, Arseus NV., with an Initial Public Offering (IPO) of 23.5 million shares on the Euronext in Brussels and Amsterdam.
A committee of the European Medicine Agency has recommended that six drugs, including one generic medicine, be authorised for marketing in the European Union.
The UK Medical Research Council (MRC) said that it will fund a research project from the North East England Stem Cell Institute that involves partially financing in vitro fertilisation (IVF) treatments for women who donate their surplus eggs for stem-cell research.
Researchers at University College London and Novozymes Delta UK Ltd are working together to develop potential therapeutics for cancer.
Oxford BioMedica Plc said that it has reached the first development milestone in its collaboration with Sanofi-Aventis to produce a cancer immunotherapy product, leading to a payment of €9 million. The product, TroVax, targets the tumour antigen 5T4 which appears in a wide range of solid tumours.
Evotec AG has reached an agreement to acquire Renovis Inc of San Francisco, California, in an all stock transaction valued at about $151.8 million
A committee of the European Medicine Agency has recommended that 17 new products qualify for financial and regulatory incentives because they meet the European criteria for orphan medicines. Orphan products are intended to treat serious or life-threatening diseases that affect not more than 5 out of 10,000 persons in the European Union. Producers of orphan designated drugs may be eligible for grants and regulatory fee reductions.
IDEA AG, a privately held German biopharmaceutical company, has licensed its non-steroidal, anti-inflammatory drug and delivery product, Diractin, to Alpharma Ireland Ltd, an affiliate of Alpharma Inc., a US specialty pharmaceutical company.